Zinc Absorption From SQ-LNS With and Without Phytase

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 18, 2017

Primary Completion Date

July 19, 2017

Study Completion Date

December 27, 2017

Conditions
Individuals at Risk of Zinc Deficiency
Interventions
DIETARY_SUPPLEMENT

the nutritional supplement to be used in this trial is a SQ-LNS

Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day

DIETARY_SUPPLEMENT

lipid-based nutrient supplement (SQ-LNS) with phytase

• Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration \~500 FTU/20 g SQ-LNS) added during manufacturing

DIETARY_SUPPLEMENT

0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc

delivered orally in sugar solution

DIETARY_SUPPLEMENT

1 mg isotopically enriched 68Zn

administered intravenously

Trial Locations (1)

Unknown

Keneba Clinic, Kiang

All Listed Sponsors
collaborator

University of California, Davis

OTHER

lead

London School of Hygiene and Tropical Medicine

OTHER

NCT02668133 - Zinc Absorption From SQ-LNS With and Without Phytase | Biotech Hunter | Biotech Hunter